Skip to main content

Zymeworks Inc(ZYME-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low27.95
Day High28.81
Open:28.40
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
GlobeNewswire
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Tipranks
Zymeworks Sets May 7 Date to Unveil Q1 2026 Results and Pipeline Update
GlobeNewswire
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Tipranks
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI)
Tipranks
Zymeworks Bolsters Executive Team to Drive Next Phase of Growth
GlobeNewswire
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Tipranks
Zymeworks Names Kristin Stafford as New Chief Financial Officer
GlobeNewswire
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
Tipranks
Zymeworks Wins FDA Fast Track Status for Ovarian Cancer Drug ZW191
GlobeNewswire
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Tipranks
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
Motley Fool
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Tipranks
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach
Tipranks
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting
GlobeNewswire
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
GlobeNewswire
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Tipranks
Analysts’ Top Healthcare Picks: GeneDx Holdings (WGS), Zymeworks (ZYME)
Tipranks
Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook
Tipranks
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), AbbVie (ABBV)
Tipranks
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Tipranks
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Zymeworks (ZYME) and Senseonics Holdings (SENS)
Tipranks
Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Zymeworks Monetizes Ziihera Royalties to Boost Liquidity
Tipranks
Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity
Motley Fool
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript
GlobeNewswire
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.